PBIO - Pressure BioSciences, Inc.
| Previous Close | 2.6500 |
| Open | 2.6400 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 2.5300 - 2.6400 |
| 52 Week Range | 1.2500 - 4.0300 |
| Volume | 753 |
| Avg. Volume | 9,438 |
| Market Cap | 4.942M |
| Beta (3Y Monthly) | 0.85 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -9.0880 |
| Earnings Date | Nov 12, 2019 - Nov 22, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.57 |
- Globenewswire Test
Zacks Small Cap Research Initiates Coverage on Pressure BioSciences, Inc.
SOUTH EASTON, Mass., Oct. 04, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE – Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences industry, today announced that Zacks Small Cap Research ("Zacks SCR") has initiated coverage on the Company. Copies of the new Zacks SCR report can be obtained via the following link:PBIO: Groundwork laid; opportunities abound Any opinions, judgments, estimates, or forecasts regarding the Company's historical or predicted performance or operations made by Zacks SCR are theirs alone and do not represent opinions, judgments, estimates, or forecasts of the Company or its management. The Company does not by its reference to the research prepared by Zacks SCR imply its endorsement or adoption of or concurrence with such information, conclusions, or recommendations.About Zacks Small Cap Research Zacks Small Cap Research (“Zacks SCR”) is a division of Zacks Investment Research. Zacks SCR coverage specifically looks to focus on small and micro-cap companies that are underfollowed or undervalued by Wall Street. Our analysts seek to identify and report on these companies, bringing to investors a unique opportunity to gain insight on small cap investments that are believed to be undervalued and well-positioned for future growth. Our goal is to produce high quality (institutional) research for the small cap portfolio.About Pressure BioSciences, Inc. Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.Forward Looking Statements This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "projects," "potential" or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2018, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law. Due to rounding, numbers presented throughout this and other documents may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.Investor Contacts: Richard T. Schumacher, President and CEO, (508) 230-1828 (T) Nathan P. Lawrence, Ph.D., Senior Consultant, (508) 230-1829 (F)For more information about PBI and this press release, please click on the following website link:http://www.pressurebiosciences.com Please visit us on Facebook, LinkedIn, and Twitter
- Zacks Small Cap Research
PBIO: Pressure BioSciences - Initiating Coverage
By Elizabeth Senko, CFA OTC:PBIO READ THE FULL PBIO RESEARCH REPORT OUTLOOK : Pressure BioSciences (OTC:PBIO) is at a tipping point. Demand grew modestly through its early years but is expected to accelerate starting in 2020. After a decade of marketing its original PCT sample preparation platform to academic opinion leaders and early research customers, the
- GlobeNewswire
Pressure BioSciences’ Proprietary PCT Platform Fills Pivotal Role for Tumor Analyses in Novel Workflow Presented at Leading Global Gynecologic Cancer Meeting
SOUTH EASTON, Mass., Oct. 01, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE – Pressure BioSciences, Inc. (PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences industry, today announced the Company’s patented pressure cycling technology (“PCT”) platform was featured as an integral part of a new, innovative workflow for the analysis of proteins from cancer biopsy samples. This workflow was presented in a plenary session at the Annual Meeting of the International Gynecologic Cancer Society (“IGCS”) on September 21, 2019 in Rio de Janeiro, Brazil. The mission of the IGCS is to improve the care and outcomes for women with gynecologic cancer worldwide through education, training and public awareness.
- ACCESSWIRE
Pressure BioSciences Provides Corporate Update, Focus on CBD Market and Growth Drivers for 2019-2020 in New SNNLive Video Interview on StockNewsNow.com
LOS ANGELES, CA / ACCESSWIRE / September 27, 2019 / StockNewsNow.com , The Official MicroCap News Source™, today published an SNNLive Video Interview with Richard T. Schumacher, President and CEO of Pressure ...
- GlobeNewswire
Pressure BioSciences’ PCT Platform Featured in Multiple Presentations at Major International Science Conference
International HUPO plays a pivotal role in defining and promoting proteomics through international cooperation and collaborations by fostering the development of new technologies, techniques, and training to better understand the full complement and roles of proteins in human health and disease. The multiple PCT-related presentations included development of new methods and applications using PBI’s unique PCT platform to advance knowledge and understanding in areas such as cancer research, with particular focus on cancer biomarker discovery. Ms. Roxana McCloskey, PBI's Global Director of Sales & Marketing, commented: "We are delighted to note that the number of PCT-related presentations at important international meetings is now exploding, in response to our years of investment in building collaborations and supporting research and the publication of now over 150 peer-reviewed scientific articles.
- Newsfile
Pressure BioSciences, Inc. Discusses Major Advancements Its PCT, BaroFold, and BaroShear K45 Platforms
Phoenix, Arizona--(Newsfile Corp. - September 18, 2019) - The Stock Day Podcast recently welcomed Mr. Richard T. Schumacher, President and CEO of Pressure BioSciences, Inc. (OTCQB: PBIO) ("the Company"), to discuss PBIO on Stock Day with its host Mr. Everett Jolley. PBIO is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry.Mr. Jolly began the interview by welcoming Mr. Schumacher back to the ...
- GlobeNewswire
Pressure BioSciences Prepares for Growth, Adding Daniel J. Shea as Chief Financial Officer
Shea’s 30-Year Diverse Experience in Acquisitions, Capital Markets, SEC Reporting, and Leading Financial Organizations Bolsters PBI’s Strong Senior Management Team South.
- GlobeNewswire
Pressure BioSciences’ PCT Platform Identified as Pivotal for Cancer Biomarker Discovery and for Potential Clinical Diagnostics
SOUTH EASTON, MA, Sept. 10, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Pressure BioSciences, Inc. (PBIO) (“PBI” and the “Company”) is a leader in the development and sale of innovative, broadly enabling, pressure-based instruments and related consumables for the worldwide life sciences and other industries. The Company announced today the publication of two scientific journal articles, led by independent teams of scientists in China and Australia, reporting excellent results with PBI’s Pressure Cycling Technology (“PCT”) platform in processing preserved formalin-fixed paraffin-embedded (“FFPE”) and fresh frozen biopsy tissue samples for discovery and elucidation of cancer biomarkers and potentially for use in clinical diagnostics based upon these markers. The Chinese team from Westlake University (Hangzhou, China) purchased their first two PCT platforms in 2017 and subsequently purchased four additional PCT systems. The Australian Proteome of Human Cancer (“ProCan”) team bought their first PCT system in 2016 and have subsequently added five more PCT platforms.
- Newsfile
InvestmentPitch Media Video Discusses Pressure BioSciences' Two Purchase Orders for its Revolutionary BaroShear(tm) K45 Processing System for CBD Nanoemulsion - Video Available on Investmentpitch.com
Vancouver, British Columbia--(Newsfile Corp. - August 27, 2019) - Pressure BioSciences, Inc. (OTCQB: PBIO) announced two additional purchase orders for its revolutionary BaroShear™ K45 processing system. Based on the company's proprietary Ultra Shear Technology™ (UST™) platform, the BaroShear K45 is a unique and powerful nanoemulsification system designed to resolve one of the most critical problems facing CBD manufacturers today: the extremely poor solubility of CBD Oil in water. Cannot view this video? ...
- GlobeNewswire
Pressure BioSciences Announces Two More Purchase Orders for its Revolutionary BaroShear K45 Processing System for Manufacturing Water-Soluble CBD
SOUTH EASTON, MA, Aug. 22, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Pressure BioSciences, Inc. (PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences industry, today announced it has received two additional purchase orders for its revolutionary BaroShear™ K45 processing system. This novel processing system is based on the Company’s proprietary Ultra Shear Technology™ (UST™) platform. The BaroShear K45 is a unique and powerful nanoemulsification system designed to resolve one of the most critical problems facing the CBD industry today: the extremely poor solubility of CBD Oil in water.
- ACCESSWIRE
Pressure BioSciences, Inc. Reports Second Quarter 2019 Financial Results and Provides Business Update
Record Consumables Sales, Strong Growth in BaroFold & UST Services, and Launch of Revolutionary CBD Processing System Highlight the 2019 Second Quarter; Company Believes Total Revenue Will More than Double ...
- Newsfile
Stock Day Media Shares Discovery of Revolutionary Technology that Can Make High Quality, Highly Stable, Water-Soluble Nanoemulsions of CBD Oil with Pressure and Shear (Physics), Not Chemicals
Phoenix, Arizona--(Newsfile Corp. - August 14, 2019) - Stock Day Media prides itself in discovering companies with highly talented staff, revolutionary technologies, and the experience to combine these two key assets to change an industry. We have been watching an intriguing company for several years now, and with the news they recently released, we believe they are truly a company that has the talent, technology, experience, patent protection, and know-how to change ...
- ACCESSWIRE
Pressure BioSciences, Inc. to Discuss Second Quarter 2019 Financial Results and Provide Business Update
Conference Call Scheduled for Thursday, August 15 th at 4:30pm ET SOUTH EASTON, MA / ACCESSWIRE / August 13, 2019 / Pressure BioSciences, Inc. (OTCQB:PBIO) (“PBI” and the “Company”) today announced that ...
- ACCESSWIRE
Pressure BioSciences Announces First Close and Customer for its Revolutionary Water-Soluble CBD Manufacturing System, the BaroShear K45
SOUTH EASTON, MA / ACCESSWIRE / July 25, 2019 / Pressure BioSciences, Inc. (PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences industry, today announced the initial sale of its revolutionary BaroShear™ K45 processing system. This novel instrument system is based on the Company’s proprietary Ultra Shear Technology™ (UST™) platform.
- ACCESSWIRE
Pressure BioSciences Announces Second Major Contract Utilizing its BaroFold Protein Refolding and Disaggregation Biopharma Services
SOUTH EASTON, MA / ACCESSWIRE / July 24, 2019 / Pressure BioSciences, Inc. (PBIO) (“PBI” and the “Company”), a leader in the development and sale of broadly enabling, high pressure-based instruments, platform technologies and related consumables for the worldwide life sciences industry, today announced it has signed a contract services agreement with a world-renown, multi-billion dollar biotherapeutics company to enhance the process manufacturing of one of their candidate protein drugs. The manufacturing of therapeutic proteins can be a complex and challenging process.
- ACCESSWIRE
Pressure BioSciences' PCT Platform Highlighted at International Conference in China
SOUTH EASTON, MA / ACCESSWIRE / July 18, 2019 / Pressure BioSciences, Inc. (PBIO) (“PBI” and the “Company”), a leader in the development and sale of innovative, broadly enabling, pressure-based instruments and related consumables for the worldwide life sciences and other industries, today announced that its flagship Barocycler 2320EXTREME instrument was prominently featured at a three-day, internationally-attended scientific conference held at the elite Westlake University (“Westlake”) in Hangzhou, China. One of the primary conference organizers was Professor Tiannan Guo, MD., PhD, a well-known protein research scientist. In 2017, Professor Guo’s Westlake laboratory was named a PBI Center of Excellence.
- ACCESSWIRE
Pressure BioSciences Enters CBD Market with Launch of Novel Instrument System to Revolutionize Manufacturing of High Quality, Water-Soluble CBD
SOUTH EASTON, MA / ACCESSWIRE / June 27, 2019 / Pressure BioSciences, Inc. (PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences industry, today announced the launch of its BaroShear™ K45 system based on the Company's proprietary Ultra Shear Technology™ (UST™) platform. The BaroShear K45 system is a unique and powerful next generation nanoemulsification system designed to fix one of the most critical problems facing CBD manufacturers today: the extremely poor water solubility of CBD oil. Because of these solubility issues, many CBD products on the market today contain an inefficient over-abundance of CBD and/or undesirable chemicals to try and improve its solubility in water.
- ACCESSWIRE
Pressure BioSciences Announces Achievement of First Major Milestone in Development of Potential Breakthrough Processing Method for Higher Quality and Safer Food and Beverages
Proprietary, Custom Built UST-Based Instrument Delivered to Collaborators at The Ohio State University; OSU Scientists to Study Pressure and Shear Effects on Pathogen Inactivation, Stability, and Quality ...
- ACCESSWIRE
Pressure BioSciences' Ultra High Pressure HUB Platform Highly Effective in Studies to Develop Improved Methods for Food Safety
HUB Platform Plays Critical Role in Innovative Research Studies Designed to Increase Understanding of and Develop Methods for the Prevention of Serious Food-Borne Diseases Caused by E. coli and Listeria ...
- ACCESSWIRE
Pressure BioSciences' PCT Platform Prominently Featured in Record Number of Presentations at Major International Science Conference
SOUTH EASTON, MA / ACCESSWIRE / June 12, 2019 / Pressure BioSciences, Inc. (PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-base instruments, consumables, and platform technology solutions to the worldwide life sciences industry, today announced that the Company's patented pressure cycling technology ("PCT") platform was prominently featured in 15 independent presentations at the annual conference of the American Society for Mass Spectrometry ("ASMS"), held from June 1-6, 2019 in Atlanta, GA. The presentations spanned wide ranging applications for PBI's unique PCT platform in scientific studies, particularly their essential use in advancing knowledge and understanding in such areas as cancer research, protein function, molecular biology, and biomarker discovery.
- ACCESSWIRE
Pressure BioSciences, Inc. Reports First Quarter 2019 Financial Results and Provides Business Update
Q1 Revenue from Newly Created BioPharma and UST Contract Services Significantly Exceeds Services Revenue for All Quarters of 2018 Combined Investor Conference Call Scheduled for Thursday, May 16, 2019 ...
- ACCESSWIRE
Pressure BioSciences, Inc. to Discuss First Quarter 2019 Financial Results and Provide Business Update
Conference Call Scheduled for Thursday, May 16 th at 4:30pm ET SOUTH EASTON, MA / ACCESSWIRE / May 15, 2019 / Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company") today ...
- ACCESSWIRE
Pressure BioSciences Announces CEO Succession Plan
SOUTH EASTON, MA / ACCESSWIRE / May 1, 2019 / Pressure BioSciences, Inc. (PBIO) ("PBI" and the "Company"), a leader in the development and sale of innovative, broadly enabling, pressure-based instruments and related consumables for the worldwide life sciences industry, today announced that Mr. Richard T. Schumacher, the Founder of the Company, notified the Company's Board of Directors on April 25, 2019 that he plans to step down as President and CEO effective September 9, 2019. Mr. Schumacher has been working with the Company's Board of Directors on leadership succession planning for many months, including the selection of Bradford A. Young, PhD, MBA, as SVP & Chief Commercial Officer ("CCO") for the Company in November 2018.
- ACCESSWIRE
Pressure BioSciences, Inc. Reports Record Fourth Quarter and Fiscal Year 2018 Financial Results and Provides Business Update
Q4 2018 Total Revenue Increases 37% over Q4 2017, Setting New Record Quarterly High; FY 2018 Total Revenue Increases 10% over FY 2017, Setting New Record Annual High; Initial Revenue Reported from New ...